Lipidomic Profiling Unveils Sex Differences in Diabetes Risk: Implications for Precision Medicine

Type 2 diabetes (T2D) is a multifactorial condition whose greatest impact comes from its complications. Not only impaired glucose homeostasis, but also lipid alterations have a relevant role, with insulin derived mechanisms behind this milieu, i.e., glycemia and lipidemia. Thus, we hypothesized that a) distinct glucose and lipid profiles and b) sex differences, particularly in lipids patterns, may be used to identify subjects at higher risk to develop T2D. The PREVADIAB2 study evaluated metabolic alterations after 5 years in subjects without T2D when participating to PREVADIAB1. Herein, 953 subjects from the PREVADIAB2 cohort were stratified using a hierarchical clustering algorithm, informed by HOMA-IR, IGI, fISR and fIC. The resulting clusters were profiled and the lipidome of a subset (n=488) was assessed by LC/MS-QTOF. We identified four clusters, named according to their main metabolic features: Liver Sensitive (LS); Pancreas Glucose Sensitive (PGS); Insulin Deficient (ID); and Insulin Resistant (IR). These cluster metabolic patterns were similar between sexes. However, men and women had distinct parameters cut-offs and lipidomic profiles. Overall, women presented higher long chain ceramides. Nonetheless, men had higher ceramide to sphingomyelin ratio and higher lysophosphatidylcholine to phosphatidylcholine ratio. For both genders, the LS cluster had the most advantageous lipid profile, whereas the other clusters presented lipid specificities towards dysmetabolism. This work shows that clustering individuals by distinct insulin-related metabolic features and sex identifies different phenotypes with distinct lipidome profile, thus demonstrating the importance of placing diabetes in a broader context of metabolism beyond glucose.

[1]  Yan Liu,et al.  Specific triacylglycerol, diacylglycerol, and lyso-phosphatidylcholine species for the prediction of type 2 diabetes: a ~ 16-year prospective study in Chinese , 2022, Cardiovascular Diabetology.

[2]  R. Gabbay,et al.  Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) , 2022, Diabetologia.

[3]  W. Jia,et al.  Serum lipidomics profiles reveal potential lipid markers for prediabetes and type 2 diabetes in patients from multiple communities , 2022, Frontiers in Endocrinology.

[4]  M. Wenk,et al.  Clinical variable-based cluster analysis identifies novel subgroups with a distinct genetic signature, lipidomic pattern and cardio-renal risks in Asian patients with recent-onset type 2 diabetes , 2022, Diabetologia.

[5]  R. DeFronzo,et al.  Effects of sustained hyperglycemia on skeletal muscle lipids in healthy subjects. , 2022, The Journal of clinical endocrinology and metabolism.

[6]  M. Allison,et al.  Metabolic signatures across the full spectrum of non-alcoholic fatty liver disease , 2022, JHEP reports : innovation in hepatology.

[7]  E. Huang,et al.  2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2022. , 2021, Diabetes care.

[8]  Xiaojian Zhang,et al.  Association of Coronary Artery Disease and Metabolic Syndrome: Usefulness of Serum Metabolomics Approach , 2021, Frontiers in Endocrinology.

[9]  M. Orešič,et al.  Metabolomics and lipidomics in NAFLD: biomarkers and non-invasive diagnostic tests , 2021, Nature Reviews Gastroenterology & Hepatology.

[10]  R. Choi,et al.  Ceramides and other sphingolipids as drivers of cardiovascular disease , 2021, Nature Reviews Cardiology.

[11]  L. Liang,et al.  Associations among circulating sphingolipids, β-cell function, and risk of developing type 2 diabetes: A population-based cohort study in China , 2020, PLoS medicine.

[12]  R. DeFronzo,et al.  Adaptation of Insulin Clearance to Metabolic Demand Is a Key Determinant of Glucose Tolerance , 2020, Diabetes.

[13]  P. Scherer,et al.  The Role of Ceramides in Diabetes and Cardiovascular Disease Regulation of Ceramides by Adipokines , 2020, Frontiers in Endocrinology.

[14]  É. Hajduch,et al.  Sphingolipid Metabolism and Signaling in Skeletal Muscle: From Physiology to Physiopathology , 2020, Frontiers in Endocrinology.

[15]  C. Penha-Gonçalves,et al.  Metabolic Footprint, towards Understanding Type 2 Diabetes beyond Glycemia , 2020, Journal of clinical medicine.

[16]  D. Owens,et al.  Review of Methods for Detecting Glycemic Disorders. , 2020, Diabetes research and clinical practice.

[17]  Ahmed Mohamed,et al.  lipidr: a software tool for data mining and analysis of lipidomics datasets. , 2020, Journal of proteome research.

[18]  D. Levy,et al.  Lipidomic profiling identifies signatures of metabolic risk , 2019, EBioMedicine.

[19]  Rohit Loomba,et al.  Noninvasive Assessment of Liver Disease in Patients With Nonalcoholic Fatty Liver Disease. , 2019, Gastroenterology.

[20]  L. Liang,et al.  Plasma Lipidomic Profiling and Risk of Type 2 Diabetes in the PREDIMED Trial , 2018, Diabetes Care.

[21]  Dermot F. Reilly,et al.  Relation of plasma ceramides to visceral adiposity, insulin resistance and the development of type 2 diabetes mellitus: the Dallas Heart Study , 2018, Diabetologia.

[22]  L. Groop,et al.  Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables. , 2018, The lancet. Diabetes & endocrinology.

[23]  A. Gastaldelli,et al.  Beta‐cell sensitivity to glucose is impaired after gastric bypass surgery , 2018, Diabetes, obesity & metabolism.

[24]  Jian Wang,et al.  Lipidomic profiling reveals distinct differences in plasma lipid composition in healthy, prediabetic, and type 2 diabetic individuals , 2017, GigaScience.

[25]  Ioannis Xenarios,et al.  Plasma Dihydroceramides Are Diabetes Susceptibility Biomarker Candidates in Mice and Humans. , 2017, Cell reports.

[26]  Amalia Gastaldelli,et al.  Role of Adipose Tissue Insulin Resistance in the Natural History of Type 2 Diabetes: Results From the San Antonio Metabolism Study , 2017, Diabetes.

[27]  Xianlin Han,et al.  Lipidomics for studying metabolism , 2016, Nature Reviews Endocrinology.

[28]  Stefan Lehr,et al.  Lipidomics—Reshaping the Analysis and Perception of Type 2 Diabetes , 2016, International journal of molecular sciences.

[29]  Wei Zhu,et al.  Comprehensive Metabolomic Characterization of Coronary Artery Diseases. , 2016, Journal of the American College of Cardiology.

[30]  Kim Ekroos,et al.  Plasma ceramides predict cardiovascular death in patients with stable coronary artery disease and acute coronary syndromes beyond LDL-cholesterol , 2016, European heart journal.

[31]  J. Shaw,et al.  Lipidomic risk score independently and cost-effectively predicts risk of future type 2 diabetes: results from diverse cohorts , 2016, Lipids in Health and Disease.

[32]  S. Neubauer,et al.  Sex-Specific Differences in Hepatic Fat Oxidation and Synthesis May Explain the Higher Propensity for NAFLD in Men. , 2015, The Journal of clinical endocrinology and metabolism.

[33]  Malika Charrad,et al.  NbClust: An R Package for Determining the Relevant Number of Clusters in a Data Set , 2014 .

[34]  A. Corcelli,et al.  A fast method for the determination of the PC/LPC ratio in intact serum by MALDI-TOF MS: an easy-to-follow lipid biomarker of inflammation. , 2014, Chemistry and physics of lipids.

[35]  G. Bray,et al.  Prediction of Diabetes Based on Baseline Metabolic Characteristics in Individuals at High Risk , 2013, Diabetes Care.

[36]  Yoshiro Saito,et al.  Plasma and serum from nonfasting men and women differ in their lipidomic profiles. , 2013, Biological & pharmaceutical bulletin.

[37]  P. Meikle,et al.  Roles of ceramide and sphingolipids in pancreatic β-cell function and dysfunction , 2012, Islets.

[38]  J. Kastelein,et al.  Carriers of lecithin cholesterol acyltransferase gene mutations have accelerated atherogenesis as assessed by carotid 3.0-T magnetic resonance imaging [corrected]. , 2011, Journal of the American College of Cardiology.

[39]  S. Summers,et al.  Ceramides as modulators of cellular and whole-body metabolism. , 2011, The Journal of clinical investigation.

[40]  Y. Liu,et al.  An Introduction to Sphingolipid Metabolism and Analysis by New Technologies , 2010, NeuroMolecular Medicine.

[41]  J. Boavida,et al.  First diabetes prevalence study in Portugal: PREVADIAB study , 2010, Diabetic medicine : a journal of the British Diabetic Association.

[42]  N. Lundbom,et al.  Prediction of non-alcoholic fatty liver disease and liver fat using metabolic and genetic factors. , 2009, Gastroenterology.

[43]  R. DeFronzo,et al.  Oral Disposition Index Predicts the Development of Future Diabetes Above and Beyond Fasting and 2-h Glucose Levels , 2009, Diabetes Care.

[44]  T. J. Cunningham,et al.  Product inhibition of secreted phospholipase A2 may explain lysophosphatidylcholines' unexpected therapeutic properties , 2008, Journal of Inflammation.

[45]  M. Matsuda,et al.  Muscle and Liver Insulin Resistance Indexes Derived From the Oral Glucose Tolerance Test , 2007, Diabetes Care.

[46]  R. Rabasa-Lhoret,et al.  Muscle and Liver Insulin Resistance Indexes Derived From the Oral Glucose Tolerance Test , 2007, Diabetes Care.

[47]  R. Matthiesen Mass Spectrometry Data Analysis in Proteomics , 2006, Methods in Molecular Biology.

[48]  M. Cnop,et al.  Beta-cell function is a major contributor to oral glucose tolerance in high-risk relatives of four ethnic groups in the U.S. , 2002, Diabetes.

[49]  C. Kahn,et al.  Insulin signalling and the regulation of glucose and lipid metabolism , 2001, Nature.

[50]  M. T. Brennan,et al.  Insulin secretion in response to glycemic stimulus: relation of delayed initial release to carbohydrate intolerance in mild diabetes mellitus. , 1967, The Journal of clinical investigation.

[51]  Roberto Henriques,et al.  Clustering Clinical Data in R. , 2020, Methods in molecular biology.

[52]  Tommi Suvitaival,et al.  Lipidome as a predictive tool in progression to type 2 diabetes in Finnish men. , 2018, Metabolism: clinical and experimental.

[53]  Karin Kraft,et al.  [Type-2 diabetes]. , 2010, MMW Fortschritte der Medizin.

[54]  Robert K. Murray,et al.  Harper's Illustrated Biochemistry , 2003 .

[55]  M. Matsuda,et al.  Beta-cell dysfunction and glucose intolerance: results from the San Antonio metabolism (SAM) study , 2003, Diabetologia.

[56]  M. Cnop,et al.  - Cell Function Is a Major Contributor to Oral Glucose Tolerance in High-Risk Relatives of Four Ethnic Groups in the U . , 2002 .

[57]  M. Balabolkin,et al.  [Classification of diabetes mellitus]. , 1980, Terapevticheskii arkhiv.